-
2301por Motlová, Lucia, Šnajdr, Ivan, Kutil, Zsófia, Andris, Erik, Ptáček, Jakub, Novotná, Adéla, Nováková, Zora, Havlínová, Barbora, Tueckmantel, Werner, Dráberová, Helena, Majer, Pavel, Schutkowski, Mike, Kozikowski, Alan, Rulíšek, Lubomír, Bařinka, Cyril“…We also clearly (and quantitatively) explain the role of the −CF(3) or −CHF(2) substituent on the oxadiazole ring, which is a prerequisite for hydrolysis to occur. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2302por Salati, Victoria, Mandralis, Katerina, Becce, Fabio, Koerfer, Joachim, Lambercy, Karma, Simon, Christian, Gorostidi, François“…No difference in median LOS was observed (41 vs. 33 days, p = 0.295), nor in treatment costs (119,976 vs. 109,402 CHF, p = 0.585). The median overall survival was comparable between the two groups (3.43 vs. 4.95 years, p = 0.09). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2303Publicado 2014“…Accountable care organizations (ACOs) are 1 component of this evolution, and 1 of their charges is to reduce hospital readmission rates for key diagnoses such as congestive heart failure (CHF) and other cardiovascular comorbidities. Lack of patient follow-up and adherence are 2 major causes of readmission. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2304por Tabella, Erika, Correale, Michele, Alcidi, Gianmarco, Pugliese, Rosanna, Ioannoni, Sara, Romano, Matteo, Palmieri, Gianpaolo, Di Biase, Matteo, Brunetti, Natale Daniele, Iacoviello, Massimo“…Methods: Consecutive patients affected by chronic heart failure (CHF) were evaluated beginning in January 2022. At the baseline clinical visit, both the patient’s current medication and the prescribed treatments were recorded. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2305por Mahmoud, Alkhansa, Casciati, Arianna, Bakar, Zuki Abu, Hamzah, Hazilawati, Ahmad, Tengku Ahbrizal Tengku, Noor, Mohd Hezmee Mohd“…MCF7 and MDA-MD-231 were irradiated with different radiation doses using a Gilardoni CHF 320 G X-ray generator (Mandello del Lario, Italy) at 250 kVp, 15 mA [with half-value layer (HVL) = 1.6 mm copper]. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2306por Turer, Aslan T, Mahaffey, Kenneth W, Gallup, Dianne, Weaver, W Douglas, Christenson, Robert H, Every, Nathan R, Ohman, E Magnus“…CONCLUSION: Peak CK and CK-MB values and AUC calculations have significant correlation with functional outcomes (LVEF- and SPECT-determined infarct size) and death or CHF outcomes in the setting of STEMI. Cardiac biomarkers provide prognostic information and may serve as valid endpoint measurements for phase II clinical trials.…”
Publicado 2005
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2307por Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., van Oosterom, A. T.“…Nine patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no statistical differences in response rate and survival were found between the two treatment arms. …”
Publicado 1998
Enlace del recurso
Enlace del recurso
Texto -
2308por Nijjar, Aman PK, Wang, Hong, Dasgupta, Kaberi, Rabi, Doreen M, Quan, Hude, Khan, Nadia A“…We measured the risk of developing a composite cardiovascular outcome of recurrent AMI, congestive heart failure (CHF) requiring hospitalization, or death, in these two groups. …”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2309por Stahrenberg, R., Edelmann, F., Mende, M., Kockskämper, A., Düngen, H. D., Scherer, M., Kochen, M. M., Binder, L., Herrmann-Lingen, C., Gelbrich, G., Hasenfuß, G., Pieske, B., Wachter, R.“…METHODS: In the observational Diagnostic Trial on Prevalence and Clinical Course of Diastolic Dysfunction and Diastolic Heart Failure (DIAST-CHF) study, patients with risk factors for heart failure were included. …”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2310por Bachoura, Abdo, Guitton, Thierry G., Smith, R. Malcolm, Vrahas, Mark S., Zurakowski, David, Ring, David“…RESULTS: Six factors independently predicted SSI: (1) the use of a drain, OR 2.3, 95% CI (1.3–3.8); (2) number of operations OR 3.4, 95% CI (2.0–6.0); (3) diabetes, OR 2.1, 95% CI (1.2–3.8); (4) congestive heart failure (CHF), OR 2.8, 95% CI (1.3–6.5); (5) site of injury tibial shaft/plateau, OR 2.3, 95% CI (1.3–4.2); and (6) site of injury, elbow, OR 2.2, 95% CI (1.1–4.7). …”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2311por Shoukat, Sana, Gowani, Saqib A, Taqui, Ather M, Ul Hassan, Rameez, Bhutta, Zain A, Malik, Anum I, Sherjeel, Sajjad A, Sheheryar, Quratulanne, Dhakam, Sajid H“…The survey showed a very high awareness of CHF guidelines; 97.4% aware of any guideline. About 13.8% considered ESC guidelines as relevant or very relevant for guiding treatment decisions while 92.8% chose AHA guidelines in relevance. 87.2% of respondents perceived that they adhered to the HF guidelines. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2312por Kong, Shan-Shan, Liu, Jin-Jun, Hwang, Tyzh-Chang, Yu, Xiao-Jiang, Zhao, Mei, Zhao, Ming, Yuan, Bing-Xiang, Lu, Yi, Kang, Yu-Ming, Wang, Bing, Zang, Wei-Jin“…Vagus nerve stimulation (VNS) has been shown to improve left ventricular function and survival in rats with acute myocardial infarction (AMI), and this maneuver has also been adopted clinically for the treatment of patients with chronic heart failure (CHF). Recent in vitro and in vivo studies have suggested that VNS can modulate the level of pro-inflammatory factors. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2313por Etter, Jean-François“…Financial rewards will be offered for biochemically verified smoking abstinence after 1, 2, and 3 weeks and 1, 3, and 6 months, for a maximum of 1,500 CHF (1,250 EUR, 1,500 USD) for those abstinent at all time-points. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2314por Schneider, Andreas, Schneider, Markus P, Scharnagl, Hubert, Jardine, Alan G, Wanner, Christoph, Drechsler, Christiane“…RESULTS: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2315por Macdonald, Marilyn T, Lang, Ariella, Storch, Janet, Stevenson, Lynn, Barber, Tanya, Iaboni, Kristine, Donaldson, Susan“…The scoping review focused on Chronic Obstructive Pulmonary Disease (COPD), and Congestive Heart Failure (CHF); two chronic illnesses commonly managed at home and that represent frequent hospital readmissions. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2316por Campiglio, M., Bufalino, R., Sasso, M., Ferri, E., Casalini, P., Adamo, V., Fabi, A., Aiello, R., Riccardi, F., Valle, E., Scotti, V., Tabaro, G., Giuffrida, D., Tarenzi, E., Bologna, A., Mustacchi, G., Bianchi, F., Balsari, A., Ménard, S., Tagliabue, E.“…In addition, 156 patients experienced minor non-cardiac toxicities; 10 and 44 patients showed CHF and decreased LVEF, respectively, at the end of treatment. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2317por Peeters, J. M. P. W. U., Sanders-van Wijk, S., Bektas, S., Knackstedt, C., Rickenbacher, P., Nietlispach, F., Handschin, R., Maeder, M. T., Muzzarelli, S. F., Pfisterer, M. E., Brunner-La Rocca, H. P.“…METHODS AND RESULTS: This post-hoc analysis comprised 622 patients (77 ± 8 years, 76 % NYHA class ≥3, 80 % LVEF ≤45 %) participating in TIME-CHF, randomising patients to either NT-proBNP-guided or symptom-guided therapy. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2318por Diaz, Karla, Faverio, Paola, Hospenthal, Angela, Restrepo, Marcos I., Amuan, Megan E., Pugh, Mary Jo V.“…Individuals with chronic OSA were more likely to have diagnoses of congestive heart failure (CHF), pulmonary circulation disorders, COPD, and obesity and less likely to have diagnoses of hypertension, osteoarthritis, and stroke than individuals with newly diagnosed OSA. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2319por Moschetti, Karine, Favre, David, Pinget, Christophe, Pilz, Guenter, Petersen, Steffen E, Wagner, Anja, Wasserfallen, Jean-Blaise, Schwitter, Juerg“…RESULTS: CMR + CXA and CXA + FFR were equally cost-effective at a pretest likelihood of CAD of 62% in Switzerland, 65% in Germany, 83% in the UK, and 82% in the US with costs of CHF 5′794, € 1′517, £ 2′680, and $ 2′179 per patient correctly diagnosed. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2320“…[Image: see text] Rate (k) and equilibrium (K) constants for the reaction of tetrahydrofuranol with a series of Mg(2+) complexes of methyl triphosphate analogues, CH(3)O-P(O(2))-O-P(O(2))-X-PO(3)(4–), X = O, CH(2), CHCH(3), C(CH(3))(2), CFCH(3), CHF, CHCl, CHBr, CFCl, CF(2), CCl(2), and CBr(2), forming phosphate diester and pyrophosphate or bisphosphonate in aqueous solution were evaluated by B3LYP/TZVP//HF/6-31G* quantum chemical calculations and Langevin dipoles and polarized continuum solvation models. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto